Teva Pharmaceutical Industries Reports Q3 2026 Financial Results and Raises Full-Year Outlook

Teva Pharmaceutical Industries reported third-quarter 2026 revenue of $4.395 billion and adjusted EPS of $0.86. Revenue at AUSTEDO, AJOVY and UZEDY rose 21%, 61% and 96% year over year, respectively, offsetting a decline in global generics revenue. Teva raised its full-year outlook to revenue of $16.7 billion–$17.0 billion and adjusted EPS of $1.92–$2.11, and said its biosimilars business is expected to meet its 2027 revenue objective a year early. The company also cited debt refinancings and credit rating upgrades to investment grade; the article did not report a stock-price move.